drugset / Trial / NCT03099486
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU containing chemotherapy combinations.The study will enroll mCRC patients with prior progression on standard multi-agent combination chemotherapy and progression on regorafenib monotherapy.
Timeline
- Start
- 2017-10-06
- Primary completion
- 2020-06-02
- Completion
- 2020-06-02
Outcome
Outcome not reported
Stopped: “Administrative change”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 160 mg | Oral |
| Background | Leucovorin | Small molecule | 400 mg/m2 | — |
| Background | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Other |